Least Burdensome Guidance Takes Broad Approach, Alpert Tells Stakeholders
This article was originally published in The Gray Sheet
An upcoming guidance document on implementation of "least burdensome" principles at FDA's device center will provide only a broad outline of the agency's position on the issue.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.